Results 161 to 170 of about 29,303 (219)

EUS‐Guided Gallbladder Drainage for Acute Cholecystitis in the Western World: Heterogeneity in Current Practice and the Relation With Patient Outcome

open access: yesUnited European Gastroenterology Journal, Volume 14, Issue 7, September 2026.
ABSTRACT Background Laparoscopic cholecystectomy is the standard treatment for acute cholecystitis (AC), but some patients are unfit for (immediate) surgery. Endoscopic ultrasound‐guided gallbladder drainage (EUS‐GBD) using a lumen‐apposing metal stent (LAMS) is increasingly used in this population.
Louis De Wispelaere   +41 more
wiley   +1 more source

Clinical Burden of Symptomatic HEV‐3 Infection in Southern Spain

open access: yesAlimentary Pharmacology &Therapeutics, Volume 64, Issue 6, Page 792-799, September 2026.
Clinical burden of symptomatic HEV‐3 infection in southern Spain. Between 2022 and 2025, 1124 patients with acute hepatitis, defined as ALT ≥ 3 times the upper limit of normal and negative screening for HAV, HBV, HCV, EBV and CMV, were evaluated in Andalusia.
María Casares‐Jimenez   +14 more
wiley   +1 more source

Upadacitinib for anti-TNFα refractory immune checkpoint inhibitor-induced colitis: a case report. [PDF]

open access: yesTher Adv Gastroenterol
Petrousis G   +5 more
europepmc   +1 more source

Comparative Real‐World Effectiveness of Anti‐TNF, Ustekinumab and Vedolizumab in Crohn's Disease Over 24 Months: A Pooled Analysis From the Prospective UMBRELLA‐IBD Registry in Germany

open access: yesAlimentary Pharmacology &Therapeutics, Volume 64, Issue 6, Page 815-827, September 2026.
A pooled analysis from the prospective UMBRELLA‐IBD registry in Germany (n = 1567) showed comparative real‐world effectiveness in treatment persistence and clinical remission of anti‐TNF, Ustekinumab and Vedolizumab in Crohn's disease patients over 24 months.
Arne Bokemeyer   +7 more
wiley   +1 more source

Correction: Management of multicausal iatrogenic bile duct injuries with biliary fistula: Twenty-year experience in a tertiary center. [PDF]

open access: yesEndosc Int Open
Garbay V   +10 more
europepmc   +1 more source

Review Article: The Impact of the Gut Microbiome on Ulcerative Colitis Pharmacotherapy

open access: yesAlimentary Pharmacology &Therapeutics, Volume 64, Issue 6, Page 729-747, September 2026.
The gut microbiome modulates ulcerative colitis pharmacotherapy through microbial drug metabolism, immune regulation and altered drug bioavailability. Microbial composition influences response to aminosalicylates, corticosteroids, immunomodulators, biologics and small molecules, while microbiome‐targeted therapies show emerging promise.
Kate Collins   +6 more
wiley   +1 more source

Meta‐Analysis: Chronic Gastrointestinal Symptoms and Comorbidities in Hypermobile Ehlers–Danlos Syndrome and Hypermobility Spectrum Disorders

open access: yesAlimentary Pharmacology &Therapeutics, Volume 64, Issue 5, Page 574-589, September 2026.
This meta‐analysis reveals that a significant proportion of patients with hEDS/HSD experience gastrointestinal symptoms. The most prevalent symptoms include heartburn, abdominal pain, constipation, and nausea. There is a notable overlap of hEDS/HSD with chronic fatigue, DGBI, GERD, migraine, and orthostatic intolerance.
Dmitrii Kulin   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy